Pre-Made Interferon Gamma Biosimilar, Recombinant Protein targeting IFNGR1: Recombinant therapeutic protein targeting CD119/IFNGR/IMD27A/IMD27B for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-874
Pre-Made Interferon Gamma Biosimilar, Recombinant Protein targeting IFNGR1: Recombinant therapeutic protein targeting CD119/IFNGR/IMD27A/IMD27B is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
IFN-γ, or type II interferon, is a cytokine that is critical for innate and adaptive immunity against viral, some bacterial and protozoan infections. IFN-γ is an important activator of macrophages and inducer of major histocompatibility complex class II molecule expression.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
---|---|---|---|---|
GMP-Bios-INN-874-1mg | 1mg | 3090 | ||
GMP-Bios-INN-874-10mg | 10mg | Inquiry | ||
GMP-Bios-INN-874-100mg | 100mg | Inquiry | ||
GMP-Bios-INN-874-xmg | ≥100mg | Inquiry | ||
Shipping Cost: | 760.00 | |||
Total: | ||||
Description
Products Name (INN Index) | Pre-Made Interferon Gamma Biosimilar, Recombinant Protein targeting IFNGR1: Recombinant therapeutic protein targeting CD119/IFNGR/IMD27A/IMD27B |
INN Name | Interferon Gamma |
Target | IFNGR1 |
Format | Recombinant Protein |
Derivation | 0 |
Species Reactivity | human |
CH1 Isotype | IFNG (interferon gamma, IFN gamma) |
VD LC | IFNG (interferon gamma, IFN gamma) |
Highest_Clin_Trial (Jan '20) | |
Est. Status | |
100% SI Structure | |
99% SI Structure | |
95-98% SI Structure | |
Year Proposed | |
Year Recommended | |
Companies | Vidara Therapeutics Ltd. (Dublin Ireland) / Horizon Therapeutics plc (Dublin Ireland) |
Conditions Approved | |
Conditions Active | |
Conditions Discontinued | |
Development Tech | 0 |
- GENEMEDI
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
<